1 303

Cited 18 times in

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study

 Sangheun Lee  ;  Beom Kyung Kim  ;  Seung Up Kim  ;  Soo Young Park  ;  Ja Kyung Kim  ;  Hyun Woong Lee  ;  Jun Yong Park  ;  Do Young Kim  ;  Sang Hoon Ahn  ;  Won Young Tak  ;  Young Oh Kweon  ;  Jung Il Lee  ;  Kwan Sik Lee  ;  Hyung Joon Kim  ;  Kwang-Hyub Han 
 Journal of Gastroenterology and Hepatology, Vol.29(7) : 1463-1469, 2014 
Journal Title
 Journal of Gastroenterology and Hepatology 
Issue Date
Adult ; Aged ; Antineoplastic Agents/therapeutic use* ; Biomarkers, Tumor/analysis ; Carcinoma, Hepatocellular/diagnosis ; Carcinoma, Hepatocellular/drug therapy* ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Liver Neoplasms/diagnosis ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Niacinamide/analogs & derivatives* ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use* ; Predictive Value of Tests ; Prognosis ; Republic of Korea ; Retrospective Studies ; Treatment Outcome ; alpha-Fetoproteins/analysis
first-line therapy ; liver neoplasm ; prognosis ; safety ; sorafenib
BACKGROUND AND AIM: Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC). The efficacy and safety of sorafenib as a first-line therapy in Korean patients with advanced HCC were investigated. METHODS: From 2007 to 2012, 86 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) treated with sorafenib as a first-line therapy were enrolled from five tertiary hospitals. Predictors of overall survival (OS) and progression-free survival (PFS) were analyzed. RESULTS: The median age was 59.5 years, and 71 (82.6%) were males; 57 (66.3%) patients were in Child-Pugh class A. The median OS and PFS were 5.0 (range 4.0-5.9) and 3.2 (range 2.6-3.7) months, respectively. Regarding OS, Child-Pugh class A (6.0 vs 2.8 months), tumor diameter < 5 cm (6.0 vs 4.3 months), baseline α-fetoprotein < 200 ng/mL (5.8 vs 4.1 months), and the advent of hand-foot-skin reaction of ≥ grade 2 (5.9 vs 4.0 months) were independent favorable predictors (all P < 0.05). Similarly, regarding PFS, Child-Pugh class A (4.3 vs 2.1 months), tumor diameter < 5 cm (3.9 vs 2.8 months), baseline α-fetoprotein < 200 ng/mL (5.6 vs 2.8 months), and the advent of hand-foot-skin reaction of ≥ grade 2 (4.5 vs 2.6 months) were independent favorable predictors (all P < 0.05). All toxicities during sorafenib treatment were manageable. CONCLUSIONS: Because the efficacy of sorafenib seems marginal in Korean patients with treatment-naïve HCC, how to select candidates with favorable outcomes should be further investigated.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Kim, Beom Kyung(김범경) ORCID logo https://orcid.org/0000-0002-5363-2496
Kim, Seung Up(김승업) ORCID logo https://orcid.org/0000-0002-9658-8050
Kim, Ja Kyung(김자경) ORCID logo https://orcid.org/0000-0001-5025-6846
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
Lee, Sang Heun(이상헌)
Lee, Jung Il(이정일) ORCID logo https://orcid.org/0000-0002-0142-1398
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.